As advised via Pharmac Tender announcement there is to be a change in the listing and future sole supply.

New listing from 1 November 2017

Simvastatin-Mylan Tab 10 mg 90          Pharmacode  2520087                              Schedule price $0.95

Simvastatin-Mylan Tab 20 mg 90          Pharmacode  2520095                              Schedule price $1.52

Simvastatin-Mylan Tab 40 mg 90          Pharmacode  2520109                              Schedule price $2.63

Simvastatin-Mylan Tab 80 mg 90          Pharmacode  2520117                              Schedule price $6.00

Incumbent brand

Simva-Arrow Tab 10 mg 90                    Pharmacode  2316668                  Schedule price $0.95

Simva-Arrow Tab 20 mg 90                    Pharmacode  2316676                  Schedule price $1.61

Simva-Arrow Tab 40 mg 90                    Pharmacode  2316684                  Schedule price $2.83

Simva-Arrow Tab 80 mg 90                    Pharmacode  2316692                  Schedule price $7.91

Reference priced to from 1 January 2018

We would recommend you continue to purchase the incumbent and we will change automatically as existing stocks are exhausted.

 Benefit of staying with incumbent

In association with Actavis (Teva) the following prices will apply from 2 October 2017. In all cases this will provide additional margin until reference pricing kicks in 1 January 2018.

Simva-Arrow Tab 10 mg 90 – now $0.91 ex manufacturer providing an extra $0.04 per pack. Below future reference pricing.

Simva-Arrow Tab 20 mg 90 – now $1.52 ex manufacturer providing and extra $0.09 per pack. Equivalent to future reference pricing.

Simva-Arrow Tab 40 mg 90 – now $2.63 ex manufacturer providing an extra $0.20 per pack. Equivalent to future reference pricing.

Simva-Arrow Tab 80 mg 90 – now $6.90 ex manufacturer providing an extra $1.01 per pack. This is $0.90 per pack higher than future reference pricing and therefore you should be out of stock by 30 November 2017. If stock remains available after this date it will drop to reference price from 1 December 2017.

These additional margin gains may appear minimal but on volume they are significant.

Once again we need your support to ensure stock in the supply chain moves through to effectively ensure no losses are incurred.

Together we can make this a seamless and painless transition.

We thank you in anticipation of your ongoing support.

About The Author

Close